Trending Tickers: $BRZE Salesforce Buyout, $IRON Phase 3 Success, $MYGN Labcorp Deal

This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:

Braze ($BRZE) Surges on Salesforce Acquisition Agreement

Braze ($BRZE) provides software that helps companies respond to customer activity with personalized messages across apps, websites, email and other channels. On Tuesday, Salesforce agreed to acquire Braze for $47.50 per share in cash, valuing the business at approximately $5.66 billion in enterprise value. Salesforce expects Braze’s customer engagement tools to strengthen its Marketing Cloud business, particularly for companies that communicate with large numbers of consumers in real time.

The cash offer gives Braze shareholders a defined purchase price if the deal closes. Salesforce expects closing in its fiscal year 2028, subject to Braze shareholder approval, regulatory approval and other conditions. Until then, the shares can trade below the offer price to reflect the time required and the possibility that the transaction does not close as planned.

Stock Price Reaction

$BRZE closed Tuesday at $45.57, up 51.7% from the previous session. That was still $1.93 below Salesforce’s $47.50 cash offer.

Disc Medicine ($IRON) Rallies After Pivotal Trial Meets Its Goals

Disc Medicine ($IRON) is developing bitopertin for erythropoietic protoporphyria, or EPP, a rare condition that can cause severe pain after exposure to sunlight. On Monday, Disc reported that its Phase 3 APOLLO trial met both primary endpoints: lowering a substance linked to the disease and increasing the time patients could spend in light without pain. Patients taking bitopertin gained an average of 12.2 more pain-free hours in light during month six than those taking placebo. The trial also met all its secondary endpoints, including a reduction in painful reactions to light.

The result matters because the FDA declined to approve bitopertin earlier this year and wanted to see the Phase 3 results before reconsidering it. Disc plans to resubmit its application by the end of 2026 and anticipates an FDA decision by mid-2027. Bitopertin remains investigational. After the trial announcement, Disc also priced an offering of six million shares at $75 each, expected to raise $450 million before expenses if it closes. The financing could support further development and a potential launch, while increasing the number of shares outstanding.

Stock Price Reaction

$IRON closed Monday at $78.93, up 38.9%. The gain reflected a stronger potential path toward approval, although the FDA has yet to make a decision on the new data.

Myriad Genetics ($MYGN) Jumps on $210 Million Asset Sale

Myriad Genetics ($MYGN) makes genetic tests used to help guide medical decisions. On Tuesday, the company agreed to sell its Prenatal Health testing business to Labcorp ($LH) for $210 million in cash plus the value of the business’s inventory at closing. The sale includes the Prequel, Foresight, SneakPeek and FirstGene tests. Myriad says the proceeds would strengthen its balance sheet and allow it to concentrate more of its resources on cancer-related testing.

For investors, the question is what Myriad can build with a narrower business and more cash. Labcorp expects the acquired tests to generate approximately $160 million in revenue in its first year of ownership, illustrating that Myriad is selling an operating business, not simply collecting cash without giving up sales. The transaction requires regulatory clearance and other customary conditions, with closing expected by early 2027.

Stock Price Reaction

$MYGN closed Tuesday at $5.54, up 31.6%.

This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.